How much does non-invasive Down syndrome screening cost?

For some pregnant women, when they go to the hospital for prenatal check-ups, the doctor requires a minimally invasive DNA test; for some pregnant women, the doctor does not require it. Generally speaking, doctors will order minimally invasive DNA testing for older pregnant women, but those who have previously undergone Down syndrome screening do not need to do it again. Minimally invasive surgery is also a way to detect fetal malformations. How much does it cost to do non-invasive surgery during pregnancy?

How much does it cost to have non-invasive pregnancy

The price of minimally invasive DNA testing varies in every hospital and every city. It’s about 1,500 to 2,000 yuan, and it may be more expensive in more developed cities. Go to a local hospital to inquire about the price.

Minimally invasive DNA prenatal testing is also known as minimally invasive prenatal DNA testing, minimally invasive fetal sex chromosome aneuploidy testing, etc. According to the American Association of Colleges of Obstetricians and Gynaecologists, an international authoritative academic research organization, minimally invasive prenatal DNA testing (Non-invasive Prenatal Testing) is the name of the most widely used technology. The minimally invasive DNA prenatal non-destructive testing technology only uses the pregnant woman's venous blood, and uses the next-generation DNA sequencing technology to sequence the mineralogic DNA fragments (including the fetal mineralogic DNA) in the pregnant woman's jugular venous blood. The sequencing results are then analyzed for biometric characteristics, from which the fetus's genetic material can be obtained, thereby testing whether the fetus suffers from the three major sex chromosome diseases.

Minimally invasive DNA prenatal non-destructive testing technology is a safe, accurate and rapid new non-destructive testing technology for fetal sex chromosome disorders. This technology only needs to extract venous blood from pregnant women to accurately determine whether the fetus suffers from sex chromosome diseases such as Down syndrome, Maria syndrome, Patau syndrome, etc.

The blood of pregnant women contains fetal mineral DNA, which provides a practical basis for this project. Fetal chromosomal abnormalities will cause a small change in the DNA composition of the pregnant mother. This change can be analyzed and detected through deep sequencing and biological characteristics, providing theoretical significance for the new project.

Is minimally invasive DNA necessary?

Minimally invasive DNA is a method of prenatal diagnosis and confirmation using high-throughput sequencing technology. It only requires collecting more than 5 ml of jugular vein blood from the pregnant woman to obtain the fetal mineral DNA fragments contained in the jugular vein blood of the pregnant mother. Through the new generation of high-throughput sequencing DNA sequencing and biological feature analysis, the genetic material of the fetus can be known, and the risk of the fetus suffering from sex chromosome aneuploidy can be detected.

The standard clearly stipulates that there are three main groups of pregnant women who can be used for minimally invasive DNA prenatal testing:

1. In the prenatal diagnosis report, the risk rate of Down syndrome is 1/1000≤1/270, the risk rate of 18-trisomy is 1/1000≤1/350, and the risk rate of 13-trisomy is 1/1000≤1/350, which means that serological screening and imaging diagnostic tests show that common chromosomal aneuploidy is close to high risk.

2. During pregnancy, there are contraindications to invasive prenatal examinations such as threatened miscarriage, fever, bleeding tendency, and unresolved infection.

3. The baby is in the longest gestational age (more than 20 weeks and 6 days of pregnancy) and happens to be within the period when minimally invasive DNA prenatal testing can be performed. The baby has missed the best time for serological screening or the opportunity for prenatal examination, but has special requirements for reducing the risk of the three major sex chromosome diseases.